Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;9(3):214-220.
doi: 10.1016/j.jgo.2017.11.004. Epub 2017 Nov 23.

Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer

Gretchen G Kimmick  1 , Xiangrong Li  2 , Steven T Fleming  3 , Susan A Sabatino  4 , J Frank Wilson  5 , Joseph Lipscomb  6 , Rosemary Cress  7 , Carmen Bergom  5 , Roger T Anderson  8 , Xiao-Cheng Wu  2 ; Written on behalf of the Center for Disease Control and Prevention National Program of Cancer Registry Patterns of Care Study Group
Affiliations

Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer

Gretchen G Kimmick et al. J Geriatr Oncol. 2018 May.

Abstract

Objectives: To examine the associations of comorbidity and chemotherapy with breast cancer- and non-breast cancer-related death.

Materials and methods: Included were women with invasive locoregional breast cancer diagnosed in 2004 from seven population-based cancer registries. Data were abstracted from medical records and verified with treating physicians when there were inconsistencies and missing information on cancer treatment. Comorbidity severity was quantified using the Adult Comorbidity Evaluation 27. Treatment guideline concordance was determined by comparing treatment received with the National Comprehensive Cancer Network guidelines. Kaplan-Meier method and multivariable Cox proportional hazards regressions were employed for statistical analyses.

Results: Of 5852 patients, 76% were under 70years old and 69% received guideline concordant adjuvant chemotherapy. Comorbidity was more prevalent in women age 70 and older (79% vs. 51%; p<0.001). After adjusting for tumor characteristics and treatment, severe comorbidity burden was associated with significantly higher cancer-related mortality in older patients (Hazard Ratio [HR]=2.38, 95% CI 1.08-5.24), but not in younger patients (HR=1.78, 95% CI 0.87-3.64). Among patients receiving guideline adjuvant chemotherapy, cancer-related mortality was significantly higher in older patients (HR=2.35, 95% CI 1.52-3.62), and those with severe comorbidity (HR=3.79, 95% CI 1.72-8.33).

Conclusions: Findings suggest that, compared to women with no comorbidity, patients with breast cancer age 70 and older with severe comorbidity are at increased risk of dying from breast cancer, even after adjustment for adjuvant chemotherapy and other tumor and treatment differences. This information adds to risk-benefit discussions and emphasizes the need for further study of the role for adjuvant chemotherapy in these patient groups.

Keywords: Adjuvant chemotherapy; Age; Breast cancer; Comorbidity; Risk–benefit; Survival.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest/Disclosures

Dr. Kimmick has served on speakers boards and been a consultant for AstraZeneca, Pfizer, and Novartis and has had research funding from AstraZeneca, Pfizer, and Roche. Dr. Anderson has had research funding from AstraZeneca and Roche. None of the other authors have financial interests, activities, relationships, or affiliations that would pose a conflict of interest with the content of this manuscript.

Figures

Fig. 1.
Fig. 1.
Five-year cumulative cause-specific death rate (%) by age and comorbidity.
See this image and copyright information in PMC

References

    1. Wu X, Richardson LC, Kahn AR, Fulton JP, Cress RD, Shen T, et al. Survival difference between non-Hispanic black and non-Hispanic white women with localized breast cancer: the impact of guideline-concordant therapy. J Natl Med Assoc 2008;100 (5):490–8. - PubMed
    1. Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 2005;41 (5):779–85. - PubMed
    1. Land LH, Dalton SO, Jorgensen TL, Ewertz M. Comorbidity and survival after early breast cancer. A review. Crit Rev Oncol Hematol 2012;81(2):196–205. - PubMed
    1. Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Warnberg F, et al. Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat 2012;135(1):281–9. - PubMed
    1. Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer 2009;124(5):1213–9. - PubMed

Publication types